Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment

Dr. Omar Ibrahimi Chosen as Key Opinion Leader and Trainer to Instruct Other Dermatologists and Plastic Surgeons on the Use of FDA-Cleared Kybella™

Stamford, CT (PRWEB) May 27, 2015

Dr. Omar Ibrahimi, Dermatologist and Director of the Connecticut Skin Institute based in Stamford, CT has been selected as part of a controlled launch to be one of the first physicians nationwide (and the only physician in Connecticut) to offer the new FDA-cleared Kybella™ injectable which allows for the removal of submental fat (double chin). The procedure is entirely non-invasive, with little to no recovery time, no surgery and minimal risks. Dr. Ibrahimi is an invited faculty trainer for Kybella™ and will provide hands-on training for dermatologists and plastic surgeons to provide them with the necessary knowledge and guidance on the use of Kybella™ .

Kybella™ is chemically identical to the deoxycholic acid that is naturally produced by the body. Deoxycholic acid produced in the body helps the body absorb fats. When Kybella™ is injected into tissue it destroys the cell membranes of fat cells. “This is a very exciting development as it is the first reliable method for treating submental fat with a non-invasive procedure. It provides a solution to a problem area my patients have been seeking a noninvasive solution for.” – Dr. Omar Ibrahimi, Director, Connecticut Skin Institute

Kybella™ involves a series of injections into the skin, which can be repeated at monthly intervals. The safety and effectiveness of Kybella™ for treatment of submental fat were established in two clinical trials led by dermatologists which enrolled 1,022 adult participants with moderate or severe submental fat. Participants were randomly assigned to receive Kybella™ or a placebo for up to six treatments. The results showed that reductions in submental fat were observed more frequently in participants who received Kybella™ versus placebo. The most common side effects of Kybella™ include swelling, bruising, pain, numbness, redness and areas of hardness in the treatment area.

“This procedure is not liposuction, which until now has been the most effective way to treat submental fat. Liposuction involves surgery, anesthesia, incisions and mechanically removing the fat. The risks with liposuction include mycobacterial infections, scarring, and even death. With Kybella™ , the treatment entails a series of injections, and many patients can resume full activity immediately.” – Dr. Omar Ibrahimi, Director, Connecticut Skin Institute. Given these advantages, Kybella™ is quickly becoming considered the liposuction alternative.

However, the procedure requires the evaluation and skill of an experienced physician to ensure optimal results. The Connecticut Skin Institute has the added advantage in that its medical director, Dr. Omar Ibrahimi trained at Harvard Medical School for dermatology residency and completed an advanced fellowship in laser and non-invasive cosmetic procedures at the University of California. “The success of the treatment requires a proper evaluation and assessment. Simply because an office has an injectable or device does not ensure a successful and natural outcome,” says Dr. Ibrahimi.

If you would like more information about this topic, please contact the office Dr. Omar Ibrahimi at 203-428-4440 or email info(AT)ctskindoc.com. Visit http://www.ctskindoc.com for more information.

ABOUT DR. OMAR IBRAHIMI

Dr. Omar Ibrahimi is the founding and medical director of the Connecticut Skin Institute. He is a board certified dermatologist who has completed advanced fellowship training in skin cancer, laser and non-invasive cosmetic procedures . He is the first physician to offer Kybella™ to patients in Connecticut and draws patients from all of Fairfield County including Greenwich, Stamford, Darien, New Canaan, Norwalk, Wilton, Westport, Ridgefield, Westchester County and beyond.

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/05/prweb12742691.htm